Stereochemistry | ABSOLUTE |
Molecular Formula | C18H20N2O4S2 |
Molecular Weight | 392.492 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)S(=O)(=O)N[C@H]1COC[C@H]1OC2=CC=C(C=C2)C3=CC=C(S3)C#N
InChI
InChIKey=TTYKUKSFWHEBLI-DLBZAZTESA-N
InChI=1S/C18H20N2O4S2/c1-12(2)26(21,22)20-16-10-23-11-17(16)24-14-5-3-13(4-6-14)18-8-7-15(9-19)25-18/h3-8,12,16-17,20H,10-11H2,1-2H3/t16-,17+/m0/s1
Molecular Formula | C18H20N2O4S2 |
Molecular Weight | 392.492 |
Charge | 0 |
Count |
MOL RATIO
1 MOL RATIO (average) |
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
PF-04958242 is an AMPA receptor potentiator for the potential treatment of cognitive deficits in schizophrenia. But recent study revealed that there were no pharmacokinetic interactions between PF-04958242 and ketamine. 'High-impact' AMPAR potentiators like PF-04958242 may have a role in the treatment of the cognitive symptoms, but not the positive or negative symptoms, associated with schizophrenia. In addition, a clinical study was underway to evaluate the effects of PF-049582432 in subjects with age-related hearing loss in the US. PF-04958242 has been classified as glycine transporter (GLYT-1) inhibitor in this study. However, this development was discontinued.